文献速递神经核医学肿瘤 PET/CT

轻度认知障碍中[18F]氟比他班淀粉样蛋白PET负荷定量测量软件兼容性分析

Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment.
PubMed 文献 · EJNMMI Res · 2023-05-24

该回顾性队列研究对80例遗忘型轻度认知障碍患者的[18F]氟比他班淀粉样蛋白PET,用四种监管批准的商用软件以脑桥为参考区生成复合SUVr并分析兼容性。以≥0.6 SUVrpons为Aβ阳性阈值,四款软件间一致率达95%,Fleiss与Cohen kappa均≥0.9,平均ICC为0.97(95%CI 0.957-0.979)。

要点

  • 四款监管批准的商用软件对[18F]氟比他班淀粉样蛋白PET的复合SUVr定量高度相关,平均ICC为0.97(95%CI 0.957-0.979)。
  • 以≥0.6 SUVrpons为Aβ阳性阈值,四款软件间百分比一致率为95%,所有kappa≥0.9,属「几乎完美」的评定者间信度。
  • 仅两款软件报告复合z分数,其相关系数分析呈强相关(r²=0.98)。

核心结论

  • 使用优化的皮层掩膜,监管批准的软件包对[18F]氟比他班淀粉样蛋白PET提供了高度相关且可靠的定量,所用Aβ阳性阈值为≥0.6 SUVrpons。
  • 作者认为这项工作可能对进行常规临床影像的医生有价值,并鼓励在其他参考区和Centiloid量表被更多软件包实现时开展类似分析。

研究设计与样本

  • 回顾性队列研究,纳入80例遗忘型轻度认知障碍患者(男女各40例;平均年龄73岁,SD=8.52),以脑桥为参考区从[18F]氟比他班PET生成复合SUVr。
  • 基于既往尸检验证工作,采用Aβ阳性阈值≥0.6 SUVrpons。
  • 采用组内相关系数(ICC)、Aβ阳性阈值附近百分比一致率和kappa评分,分析MIM Software的MIMneuro、Syntermed的NeuroQ、Hermes Medical Solutions的BRASS和GE Healthcare的CortexID四款监管批准软件的定量结果。

主要发现

  • 以≥0.6 SUVrpons为Aβ阳性阈值,四款软件包间达成95%一致率。
  • 两例患者被其中一款软件包勉强判为Aβ阴性而其他软件包判为阳性,另有兩例患者情况相反。
  • 同一Aβ阳性阈值下,合并(Fleiss)和单个软件配对(Cohen)的所有kappa评分均≥0.9,表示「几乎完美」的评定者间信度。
  • 四款软件包复合SUVr测量间信度极好,平均测量ICC为0.97,95%CI为0.957-0.979。
  • 报告复合z分数的两款软件包间相关系数分析呈强相关(r²=0.98)。

关键数值与推荐

  • Aβ阳性阈值:≥0.6 SUVrpons,适用于以脑桥为参考区的[18F]氟比他班PET复合SUVr。
  • 四款监管批准软件包间百分比一致率:95%(以≥0.6 SUVrpons为阈值)。
  • 所有kappa评分(合并Fleiss与配对Cohen)均≥0.9,表示「几乎完美」的评定者间信度。
  • 四款软件包复合SUVr的平均测量ICC为0.97(95%CI 0.957-0.979)。
  • 两款报告复合z分数的软件包间相关系数r²=0.98。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's disease pathogenesis. In clinical practice, trained readers will visually categorise positron emission tomography (PET) scans as either Aβ positive or negative. However, adjunct quantitative analysis is becoming more widely available, where regulatory approved software can currently generate metrics such as standardised uptake value ratios (SUVr) and individual Z-scores. Therefore, it is of direct value to the imaging community to assess the compatibility of commercially available software packages. In this collaborative project, the compatibility of amyloid PET quantification was investigated across four regulatory approved software packages. In doing so, the intention is to increase visibility and understanding of clinically relevant quantitative methods. METHODS: Composite SUVr using the pons as the reference region was generated from [18F]flutemetamol (GE Healthcare) PET in a retrospective cohort of 80 amnestic mild cognitive impairment (aMCI) patients (40 each male/female; mean age = 73 years, SD = 8.52). Based on previous autopsy validation work, an Aβ positivity threshold of ≥ 0.6 SUVrpons was applied. Quantitative results from MIM Software's MIMneuro, Syntermed's NeuroQ, Hermes Medical Solutions' BRASS and GE Healthcare's CortexID were analysed using intraclass correlation coefficient (ICC), percentage agreement around the Aβ positivity threshold and kappa scores. RESULTS: Using an Aβ positivity threshold of ≥ 0.6 SUVrpons, 95% agreement was achieved across the four software packages. Two patients were narrowly classed as Aβ negative by one software package but positive by the others, and two patients vice versa. All kappa scores around the same Aβ positivity threshold, both combined (Fleiss') and individual software pairings (Cohen's), were ≥ 0.9 signifying "almost perfect" inter-rater reliability. Excellent reliability was found between composite SUVr measurements for all four software packages, with an average measure ICC of 0.97 and 95% confidence interval of 0.957-0.979. Correlation coefficient analysis between the two software packages reporting composite z-scores was strong (r2 = 0.98). CONCLUSION: Using an optimised cortical mask, regulatory approved software packages provided highly correlated and reliable quantification of [18F]flutemetamol amyloid PET with a ≥ 0.6 SUVrpons positivity threshold. In particular, this work could be of interest to physicians performing routine clinical imaging rather than researchers performing more bespoke image analysis. Similar analysis is encouraged using other reference regions as well as the Centiloid scale, when it has been implemented by more software packages.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Pemberton HG, Buckley C, Battle M, et al. Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment. EJNMMI Res. 2023. PMID: 37225974. doi:10.1186/s13550-023-00994-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。